Home » Pipeline
Pipeline
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| Triple-Gene LLC | INXN-4001 | heart failure | Phase 1 trial initiated enrolling 12 stable subjects with implanted Left Ventricular Assist Device (LVAD) |
| Cerveau Technologies Inc. | [F18]MK-6240 | neurodegenerative diseases | Phase 1 trial initiated enrolling healthy volunteers and subjects with Mild Cognitive Impairment (MCI) and with Alzheimer’s Disease (AD) at Kobe City Medical Center General Hospital in Japan |
| AVB-500 in combination with durvalumab | platinum-resistant, recurrent epithelial ovarian cancer | Phase 1/2 trial initiated | |
| Turning Point Therapeutics, Inc. | TPX-0046 | advanced solid tumors | Phase 1/2 trial initiated enrolling 350 TKI-treatment naïve and -pretreated subjects with RET-altered non-small-cell lung, thyroid and other advanced cancers |
| Dragonfly Therapeutics, Inc. | DF1001 | advanced solid tumors | Phase 1/2 trial initiated enrolling subjects with locally advanced or metastatic solid tumors who express HER2 |
| Turning Point Therapeutics, Inc. | repotrectinib | solid tumors | Phase 1/2 trial initiated enrolling 75 pediatric patients with ALK-, NTRK- and ROS1-positive solid tumors |
| BRII-179 (VBI-2601) | chronic hepatitis B virus (HBV) infection | Phase 1b/2a trial initiated enrolling 65 subjects | |
| xBiotech USA, Inc. | bermekimab | severe Atopic Dermatitis (AD) | Phase 2 trial initiated |
| ficlatuzumab in combination with high-dose cytarabine | relapsed and refractory acute myeloid leukemia (AML) | Phase 2 trial initiated enrolling 60 adult subjects with AML who failed induction chemotherapy or who achieved a complete response, but relapsed within one year | |
| Aptinyx Inc. | NYX-2925 | painful diabetic peripheral neuropathy (DPN) | Phase 2 trial initiated enrolling 200 subjects with advanced DPN |
| Aptinyx Inc. | NYX-2925 | fibromyalgia | Phase 2 trial initiated enrolling 300 subjects |
| Viracta Therapeutics, Inc. | nanatinostat in combination with valganciclovir | relapsed/refractory Epstein-Barr virus (EBV)-positive lymphoid malignancies | Fast Track designation granted by the FDA |
| X4 Pharmaceuticals, Inc. | mavorixafor (X4P-001) | WHIM (Warts, Hypogammaglobulinemia, Infections and Myelokathexis) syndrome | Breakthrough Therapy Designation granted by the FDA |
| Celgene Corporation | Reblozyl (luspatercept–aamt) | anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions | Approval granted by the FDA |
Upcoming Events
-
14Apr
